Key facts
- Genfleet (HKG: 02595)’s last known valuation is $799.7M (Sep 2025).
- It has raised $204.8M; the latest was Later Stage VC in Mar 2026.
- Notable investors include OrbiMed, Suzhou Guofa Venture Capital, CITIC Capital, Lake Bleu Capital, China Universal Asset Management — 10 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Genfleet (HKG: 02595)
- ·The full record, as it builds
Funding rounds
No funding rounds for Genfleet (HKG: 02595) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genfleet (HKG: 02595)
GenFleet Therapeutics (Shanghai) Inc is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. It has established a product pipeline consisting of eight product candidates with five under clinical development, including two Core Products - GFH925 and GFH375. GFH925 is an in-house discovered new drug, has been approved for commercialization in China for the treatment of advanced non-small cell lung cancer.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 68
- Website
- genfleet.com/
- Ownership
- Publicly Held
Genfleet (HKG: 02595) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genfleet (HKG: 02595) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genfleet (HKG: 02595) in its N-PORT filings yet. We sweep new filings monthly.